Drug General Information |
Drug ID |
D02XNW
|
Former ID |
DCL000259
|
Drug Name |
VX-680
|
Synonyms |
Tozasertib; MK 0457; VX 680; VX6; L-001281814; MK-045; MK-0457; Tozasertib (USAN); VX-68; MK-0457, Tozasertib, VX680, VX-680; N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide; N-(4-(4-(3-methyl-1H-pyrazol-5-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid N-(4-((4-(4-methylpiperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)pyrimidin-2-yl)sulfanyl)phenyl)amide; Cyclopropane carboxylic acid{4-[4-(4-methyl-piperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidin-2-ylsulphanyl]-phenyl}-amide; Cyclopropanecarboxylic Acid {4-[4-(4-Methyl-Piperazin-1-Yl)-6-(5-Methyl-2h-Pyrazol-3-Ylamino)-Pyrimidin-2-Ylsulfanyl]-Phenyl}-Amide
|
Drug Type |
Small molecular drug
|
Therapeutic Class |
Anticancer Agents
|
Company |
Vertex; Merck
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C23H28N8OS
|
InChI |
InChI=1S/C23H28N8OS/c1-15-13-20(29-28-15)25-19-14-21(31-11-9-30(2)10-12-31)27-23(26-19)33-18-7-5-17(6-8-18)24-22(32)16-3-4-16/h5-8,13-14,16H,3-4,9-12H2,1-2H3,(H,24,32)(H2,25,26,27,28,29)
|
InChIKey |
GCIKSSRWRFVXBI-UHFFFAOYSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
8149119, 10318339, 14907233, 22422965, 26683796, 39475635, 46394087, 46513935, 47160775, 49645761, 50100121, 51011682, 56355104, 57364809, 85246166, 91148021, 96024966, 99436958, 103023875, 103573134, 103905648, 114002454, 118844926, 123393021, 124756118, 124756963, 124788446, 125163769, 125333975, 126584085, 126647927, 126666957, 126728331, 131465120, 134221893, 134338916, 134964437, 135196779, 135631693, 135685114, 135685412, 135685413, 135685430, 135686018, 135686019, 135686032, 135686033, 136340127, 136367731, 137185042
|
Target and Pathway |
References |